AOD-9604 fat loss claims vs. what the trials actually showed

What did @coachcam.peps3 actually say?

The creator explains that AOD-9604 is a synthetic fragment of human growth hormone, specifically amino acids 176 through 191. His core argument is that this fragment promotes lipolysis and inhibits lipogenesis without raising IGF-1 or disrupting insulin sensitivity. He is careful to note that the compound doesn't burn fat automatically: "they're just going to recirculate and store back as fat" if you don't pair it with fasted exercise. He recommends morning use in a fasted state combined with cardio and L-carnitine as a fatty acid transport support. He frames AOD-9604 as a "fat loss assistant," not a magic bullet. That framing is actually one of the more responsible things you'll hear in peptide content on TikTok.

He also gives a brief mechanistic explanation, describing lipolysis as taking stored fat cells and converting them into free fatty acids to be burned in the mitochondria. This is scientifically coherent, if simplified.

Does the science back this up?

Partially, yes. The foundational research is real, but it's older and thinner than peptide promoters tend to admit. Most of what we know comes from preclinical work and one series of clinical trials from the early 2000s that didn't go as planned.

AOD-9604 was originally developed by Monash University researchers and studied by Metabolic Pharmaceuticals. Early animal studies, including work by Heffernan et al. (2001, Journal of Endocrinology), showed that the fragment did stimulate lipolysis in obese mice without the hyperglycemic effects associated with full-length growth hormone. That part of the creator's claim holds up. The IGF-1 point also checks out: because AOD-9604 lacks the receptor-binding domain of full GH, it doesn't stimulate IGF-1 production the way exogenous growth hormone does. That distinction is accurate.

However, the clinical trials in humans were disappointing. A Phase 2b trial published by Stier et al. (2013, Obesity Research and Clinical Practice) found no statistically significant difference in body weight between AOD-9604 and placebo over 24 weeks. The compound did not replicate animal results in human subjects at the doses tested. That's not a minor footnote. That's the headline.

What did they get wrong (or right)?

Credit where it's due: the creator's structural description of AOD-9604 as amino acids 176-191 of the 191-amino acid GH molecule is accurate. His mechanistic explanation of lipolysis versus lipogenesis is directionally correct. And his warning that free fatty acids won't actually be oxidized without a metabolic stimulus is genuinely good advice that many peptide promoters skip entirely.

What he glosses over is the clinical evidence gap. Describing AOD-9604 primarily through its mechanism, while omitting that the only substantial human RCT showed no significant fat loss effect, is a meaningful omission. It's not a lie, but it's selective. The L-carnitine pairing recommendation is plausible in theory, since carnitine does facilitate mitochondrial fatty acid transport, but there's no direct trial data supporting this specific combination. The creator presents it as established practice when it's essentially a theoretical stack built on two separate mechanistic rationales. That's worth flagging.

He also doesn't mention that AOD-9604 has FDA GRAS (Generally Recognized as Safe) status as a food ingredient, which is sometimes cited by sellers as regulatory approval for therapeutic use. It isn't. Those are two completely different regulatory categories.

What should you actually know?

AOD-9604 occupies a strange regulatory space. It has a real research history, a plausible mechanism, and a clinical track record that didn't deliver. Animal data and human data diverged sharply, which happens more often than peptide content creators acknowledge.

If you're considering this compound, a few facts matter. First, it is not FDA-approved as a drug. Second, compounded versions sourced from peptide suppliers vary substantially in purity and concentration, and no compounded version is equivalent to a pharmaceutical-grade product. Third, the absence of IGF-1 stimulation is genuinely a differentiating feature compared to full GH, but that doesn't automatically translate into clinical fat loss outcomes. Fourth, the fasted-state, morning-use protocol the creator describes is a reasonable harm-reduction framework, but it's based on pharmacokinetic logic, not a controlled trial testing that specific protocol.

The creator's framing as a "fat loss assistant" is intellectually honest. What's missing is the acknowledgment that even as an assistant, the human evidence is weak. That context matters for anyone weighing real financial and health decisions.